hCG: research

hCG dosage

Typical reported dose: 500–1000 units three times a week, then twice a week

• Male hypogonadotropism: six-week schedule: 500 to 1000 USP units 3 times a week for 3 weeks, then the same dose twice a week for 3 weeks three times weekly, then twice weekly, into muscle. Drug label. Studied in: Selected cases of male hypogonadotropic hypogonadism. (source)
• Male hypogonadotropism: longer course: 4000 USP units 3 times weekly for 6 to 9 months; may be reduced to 2000 USP units 3 times weekly for an additional 3 months three times weekly, into muscle. Drug label. Studied in: Selected cases of male hypogonadotropic hypogonadism. (source)
• Urinary hCG: ovulation trigger: 5000 to 10,000 USP units 1 day following the last dose of gonadotropins single trigger dose, into muscle. Drug label. Studied in: Appropriately stimulated infertile women without primary ovarian failure. (source)
• Ovidrel: 250 mcg trigger: 250 mcg one day following the last dose of the follicle stimulating agent single trigger dose, under the skin. Drug label. Studied in: Women undergoing assisted reproduction or ovulation induction. (source)
• Ovitrelle: 24–48-hour trigger: 250 mcg 24 to 48 hours after the last FSH or hMG dose single trigger dose, under the skin. Drug label. Studied in: Women after optimal follicular stimulation. (source)
• TRT study: 125 IU every other day: 125 IU every other day every other day, under the skin. Studied in a trial. Studied in: Healthy men also receiving testosterone enanthate 200 mg IM weekly. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

hCG side effects and risks

Reported side effects

• Injection-site pain, bruising or irritation: 49/335 (14.6%) with Ovidrel 250 mcg versus 92/328 (28%) with urinary hCG., mild (source)
• Ovarian hyperstimulation syndrome: 250 mcg: 4/236 (1.7%) ART; 3/99 (3.0%) OI. At 500 mcg: 8/89 (9.0%)., serious. Severe pain, rapid weight gain, vomiting or breathlessness needs urgent care. (source)
• Stomach or pelvic pain: Ovidrel ART: 10/236 (4.2%) abdominal pain., moderate (source)
• Nausea or vomiting: Ovidrel ART: nausea 8/236 (3.4%); vomiting 6/236 (2.5%)., mild (source)
• Breast growth, tenderness or acne in men: hCG/hMG: breast growth 16/182 (8.8%); acne 11/182 (6.0%)., moderate. These combination rates do not predict risk with low-dose hCG/TRT. (source)
• Water retention or swelling: unknown, moderate. Review sudden swelling, weight gain or blood-pressure change. (source)
• Headache, irritability, low mood or restlessness: unknown, moderate (source)
• Severe allergy: unknown, serious. Airway swelling, wheeze or collapse needs emergency care. (source)
• Blood clot, ovarian twisting or rupture: unknown, serious. Chest pain, one swollen leg or sudden severe pelvic pain needs urgent care. (source)
• Sperm suppression despite higher doses: Eight man study: mean 88±24 to 22±7 million/mL on 5,000 IU IM twice weekly; one azoospermic with added testosterone., serious (source)

Stop and get help if

• Severe pelvic pain, fast weight gain, vomiting, low urine output or breathlessness: Get urgent assessment for ovarian hyperstimulation.
• Chest pain, coughing blood, one swollen leg or sudden weakness: Seek emergency care for a possible blood clot.
• Throat swelling, wheeze, widespread hives or collapse: Seek emergency care for possible anaphylaxis.
• Sudden one-sided pelvic pain, fainting or shoulder pain during fertility therapy: Urgent assessment for torsion, bleeding or ectopic pregnancy.
• Fainting or palpitations while fasting or on a very low-calorie hCG diet: Get urgent assessment for dehydration or electrolyte problems.

Who should avoid it

• pregnant: Ovidrel is contraindicated in pregnancy; urinary hCG is not indicated once pregnancy is confirmed.
• breastfeeding: Use during nursing is not established; the adult self-use screen blocks it.
• tryingToConceive: Fertility use requires a semen or ovulation plan, not a size assumption.
• under18: Historic pediatric indications do not establish adult self-use regimens.
• hormoneSensitiveCancer: Sex-hormone-dependent breast, prostate or reproductive-tract tumors can be a contraindication.
• other: Prior serious hCG or excipient allergy can recur.
• other: Pituitary/hypothalamic tumors or uncontrolled thyroid/adrenal disease require assessment before gonadotropins.
• other: Primary ovarian failure, unexplained bleeding or unexplained ovarian enlargement can preclude ovulation induction.
• other: Pregnyl and Ovitrelle are contraindicated when reproductive-organ malformations are incompatible with pregnancy.
• other: Pregnyl and Ovitrelle are contraindicated when uterine fibroids are incompatible with pregnancy.
• other: Ovitrelle must not be used in postmenopausal women because an effective response cannot be obtained.
• other: Withhold an ovulation trigger when follicles, ovary size or estradiol indicate excessive response.
• heartCondition: Androgen-related water retention can worsen heart disease.
• kidneyDisease: Water retention can worsen kidney disease; renal-impairment data are limited.
• uncontrolledBloodPressure: Use cautiously with hypertension because of fluid retention.
• seizureDisorder: Urinary hCG labeling calls for caution with epilepsy.
• other: Prior clot, thrombophilia or family clotting history raises concern during fertility stimulation.
• eatingDisorderHistory: The hCG diet can reinforce harmful restriction; hCG adds no proven weight-loss benefit.
• testedAthlete: Prohibited at all times in males under WADA S2.2.1.
• other: Ovitrelle product information contraindicates active blood-clot disease.

Interactions

• Testosterone and anabolic steroids: TRT suppresses LH/FSH and can suppress sperm despite hCG. Fertility protection is not guaranteed.
• FSH or hMG: Published combinations can help selected patients; ovarian over-response and multiple pregnancy require monitoring.
• Other hCG products: Same biological pathway. Duplicate doses add exposure without a proven stacking advantage.
• Clomiphene or tamoxifen: Used in published recovery combinations; small series cannot isolate the added benefit.
• Aromatase inhibitors: Sometimes used for high estradiol; avoid automatic use without reviewing symptoms and hormones.
• Anticoagulants and injections: Review injection bruising, especially with IM dosing. No hCG-specific pharmacokinetic interaction established.

Product quality risks

• FDA warns that weight-loss drops, pellets and sprays marketed as hCG are unapproved.
• Researchers identified hCG in illegally distributed products; identity alone did not establish sterile or reliably dosed stock.
• No representative potency or contamination survey of current online hCG supply was found.

How hCG works

hCG acts like LH directly at the testes or ovaries. In men it stimulates testosterone inside the testes. In women a timed dose helps eggs finish maturing and triggers ovulation. It does not replace FSH, which may also be needed for sperm production.

• LH/chorionic gonadotropin receptor: Stimulates testicular testosterone or final follicle maturation and luteinization.
• Testicular environment: Can support testosterone inside the testes while pituitary LH stays suppressed.

Half-life: Recombinant hCG: mean terminal half-life 29±6 hours after SC administration in healthy women.